Table of Contents
Early uptake data suggest that product pipelne such as Fanapt (iloperidone; Novartis) and Latuda (lurasidone; Dainippon Sumitomo) have failed to make an impact on the schizophrenia treatment landscape. These products will find it increasingly difficult to supplant the industry leaders as generic competition heralds the end of an era for multi-billion dollar atypical antipsychotic brands....More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Robyn
+1 718 213 4904
"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...
MediPoint: Drug-Eluting Balloons - Global Analysis and Market Forecasts Summary GlobalData has released its medical devices report, “MediPoint: Drug-Eluting Balloons - Global Analysis and Market Forecasts”. ...
MediPoint: Renal Denervation - Global Analysis and Market Forecasts Summary Numerous medical device news sources and industry executives have proclaimed renal denervation to be the top medical device breakthrough ...
... To differences in known breast cancer risk factors such as reproductive hormonal factors including age at first birth or menarche and breastfeeding click to edit master subtitle style 08/11/2013 risk factors ...
... Guidelines say People with diabetes and hypertension should be treated to a systolic blood pressure goal of 140 mmhg. Lower systolic targets (such as ...
... No hepatotoxic drugs negative chronic liver disease screen establish metabolic syndrome components assess lifestyle therapeutic approaches liver specific therapies offer clinical trials advice and targets follow ...
Reportlinker.com © Copyright 2013. All rights reserved.